Monte Rosa Therapeutics, Inc.GLUENASDAQ
Loading
EBITDA Over TimeExpanding
Percentile Rank67
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

Latest
$-43.13M
↑ 35% vs avg
Percentile
P67
Within normal range
Streak
2 yr
Consecutive growthExpanding
Average
$-66.82M
Historical baseline
PeriodValueYoY Change
TTM$-43.13M+40.9%
2024$-72.99M+46.8%
2023$-137.09M-26.2%
2022$-108.64M-53.6%
2021$-70.75M-157.5%
2020$-27.47M-258.3%
2019$-7.67M-